

EXHIBIT 67

1 UNITED STATES DISTRICT COURT
 2 FOR THE NORTHERN DISTRICT OF OHIO
 3 EASTERN DIVISION

4 IN RE: NATIONAL)
 5 PRESCRIPTION) MDL No. 2804
 6 OPIATE LITIGATION)
 7 _____) Case No.
 8) 1:17-MD-2804
 9)
 10 THIS DOCUMENT RELATES) Hon. Dan A.
 11 TO ALL CASES) Polster
 12)

13 WEDNESDAY, AUGUST 1, 2018

14 HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
 15 CONFIDENTIALITY REVIEW

16 - - -

17 Videotaped deposition of Nathan J.
 18 Hartle, held at the offices of Covington &
 19 Burlington, LLP, One City Center, 850 Tenth
 20 Street Northwest, Washington, DC, commencing
 21 at 9:03 a.m., on the above date, before
 22 Carrie A. Campbell, Registered Diplomat
 23 Reporter, Certified Realtime Reporter,
 24 Illinois, California & Texas Certified
 25 Shorthand Reporter, Missouri & Kansas
 Certified Court Reporter.

- - -

GOLKOW LITIGATION SERVICES
 877.370.3377 ph | 917.591.5672 fax
 deps@golkow.com

1 is a national policy for McKesson, right?

2 MS. HENN: Objection to form.

3 QUESTIONS BY MR. RAFFERTY:

4 Q. Covers --

5 A. It covers our -- all of our
6 segments.

7 Q. Yeah, it covers everybody,
8 right?

9 Every customer that you're
10 selling narcotic painkillers to is supposed
11 to be -- McKesson is supposed to be
12 monitoring them and implementing through
13 regulatory affairs the controlled substance
14 monitoring program, correct?

15 A. Correct.

16 Q. Okay. There's not -- because
17 we saw those two regions, the east region and
18 the west region. There's not a CSMP east
19 with different policies and procedures and a
20 CSMP west with different policies and
21 procedures, is there?

22 A. There's not.

23 Q. Okay. It's just one CSMP?

24 A. Correct.

25 Q. And that CSMP covers both the

1 ISMC -- the ISMC customers as well as the RNA
2 customers, correct?

3 MS. HENN: Objection to form.

4 THE WITNESS: It does, with
5 some -- I'm sure we'll talk about this
6 later -- some unique differences for
7 this particular chain group.

8 QUESTIONS BY MR. RAFFERTY:

9 Q. Right.

10 You treat the RNAs in some ways
11 differently than you treat the small
12 pharmacies, right, or the small chain
13 pharmacies?

14 MS. HENN: Objection to form.

15 QUESTIONS BY MR. RAFFERTY:

16 Q. Inside the CSMP.

17 A. We do. Have made adjustments
18 based on the characteristics of that segment
19 in different parts of our program.

20 Q. Okay. I didn't ask you why.

21 A. Okay.

22 Q. My question was: You treat
23 them differently inside the CSMP, that you
24 treat the retail national accounts in some
25 ways in the CSMP differently than the ISMCs,

1 correct?

2 MS. HENN: Objection to form.

3 THE WITNESS: In some ways we
4 treat them different to accomplish the
5 same goals.

6 QUESTIONS BY MR. RAFFERTY:

7 Q. So my answer would be yes?

8 MS. HENN: Objection to form.

9 THE WITNESS: We do treat them
10 differently in some ways.

11 QUESTIONS BY MR. RAFFERTY:

12 Q. Okay. Thank you.

13 All right. I want to talk for
14 a few minutes about the opioid epidemic in
15 the United States.

16 First of all, you agree that
17 there is, in fact, an opioid epidemic in the
18 United States, true?

19 A. I do agree.

20 Q. And that epidemic has been
21 going on for years, correct?

22 A. Based on what I read and what I
23 know, absolutely.

24 Q. Well, you actually read and
25 know a lot of about the epidemic that's going

1 on in the country, don't you?

2 MS. HENN: Objection to form.

3 THE WITNESS: I do. That's

4 part of my responsibility -- my

5 business.

6 QUESTIONS BY MR. RAFFERTY:

7 Q. Yeah.

8 In fact, that's a big part of
9 your business is knowing exactly what's going
10 on in the country in terms of the abuse of
11 narcotic painkillers, right?

12 A. It's part of my responsibility.

13 Q. Okay.

14 A. It's why I do what I do.

15 Q. All right. In fact, you would
16 agree that this epidemic has had a
17 devastating effect on public health and
18 welfare throughout the country, true?

19 A. It has.

20 Q. And in fact, you have spoken
21 and actually given presentations about the
22 opioid epidemic in the country, correct?

23 A. I have.

24 Q. In fact, would you agree that
25 the opioid epidemic in the United States of

1 America is the deadliest drug epidemic on
2 record in our country's history?

3 A. I'm not an epidemiologist, but
4 I would believe, yes.

5 Q. Okay. Well, let's look at
6 1437.3, which we will mark as Exhibit 41 --
7 42.

8 (McKesson-Hartle Exhibit 42
9 marked for identification.)

10 QUESTIONS BY MR. RAFFERTY:

11 Q. All right, Mr. Hartle. You see
12 this controlled substance monitoring,
13 Discount Drug Mart?

14 Do you recognize that?

15 A. I absolutely do.

16 Q. Okay. And it appears, though
17 this one does have a date on it, it's
18 September 29, 2017. So not really all that
19 long ago, right?

20 A. Correct.

21 Q. Okay. Less than a year ago,
22 right?

23 A. That is.

24 Q. And you see down there Nate
25 Hartle, senior director, regulatory affairs,

1 right?

2 A. Yeah, it's my document.

3 Q. Okay. Do you recall giving
4 this presentation?

5 A. I do.

6 MR. RAFFERTY: If we could,
7 let's turn to .3, Corey.

8 QUESTIONS BY MR. RAFFERTY:

9 Q. You see that up in the top of
10 one of your slides there on page 3, a
11 headline, "Deadliest Drug Epidemic on Record
12 in Our Nation's History"?

13 Do you see that?

14 A. Yep.

15 Q. You wouldn't have put that in
16 your presentation unless you thought it was
17 true, right?

18 A. No.

19 Q. So you don't dispute that,
20 right?

21 A. I do not.

22 Q. Okay. It then goes on and
23 says, "The drug problems of past decades pale
24 when compared to the current opioid epidemic
25 which has killed 165,000 Americans from 2000

1 to 2014."

2 Did I read that right?

3 A. You did.

4 Q. Okay. Once again, you agree
5 with that statement, right?

6 A. These are part of the
7 presentation that I gave.

8 Q. Okay. If we now go to the next
9 page, page 4, it says over there, "Scope of
10 the problem." On an average day, an average
11 day in the US, more than 650,000 opioid
12 prescriptions are dispensed.

13 Do you see that?

14 A. I do.

15 Q. 3,900 people initiate
16 non-medical use of prescription opioids, and
17 then it says 580 people initiate heroin use.

18 You see that?

19 A. I see those.

20 Q. And in fact, opioid abuse and
21 addiction is a gateway to heroin use and
22 addiction, correct?

23 MS. HENN: Objection to form.

24 THE WITNESS: I'm not a medical
25 expert, but, you know, I've read

1 things, I use data from different
2 sources, and they say that.

3 QUESTIONS BY MR. RAFFERTY:

4 Q. I don't -- okay. As head of
5 regulatory affairs and the controlled
6 substance monitoring program for national
7 chains of McKesson, would you agree that in
8 fact narcotic painkiller abuse, opioid abuse,
9 is a gateway to heroin use?

10 MS. HENN: Objection to form.

11 THE WITNESS: I would agree
12 that it can be, yeah.

13 QUESTIONS BY MR. RAFFERTY:

14 Q. Okay. And in fact, 78 people
15 die from an opioid-related overdose every day
16 according to your slide.

17 Do you see that?

18 A. I see that.

19 Q. In fact, if you go on to your
20 presentation, page 16, .16, talking about the
21 heroin use, it says -- or what you say in
22 your presentation, or what you put in your
23 presentation, was people who are addicted
24 to -- and then it says, "Opioid painkillers
25 are 40 times more likely to be addicted to

1 heroin."

2 Do you see that?

3 A. I see that.

4 Q. And you agree with that?

5 A. I put them in the slides as
6 part of the information that I keep current
7 on.

8 Q. You agree with that?

9 A. Again, I'm not an expert in
10 terms of numbers, but I agree with what
11 they're putting out.

12 Q. Okay.

13 A. The concepts --

14 Q. And you wouldn't have put it
15 out there if you thought it was inaccurate,
16 right?

17 A. I would not have.

18 Q. Okay. Talking about the
19 heroin, the gateway to heroin, if we could,
20 let's have 1580.

21 (McKesson-Hartle Exhibit 43
22 marked for identification.)

23 QUESTIONS BY MR. RAFFERTY:

24 Q. This is another presentation
25 that you gave, Mr. Hartle. We'll mark this

1 as Exhibit 43. This is another presentation
2 that you gave. If you look at this --

3 MR. RAFFERTY: Corey, if you
4 could pull it up, please, 1.580 --
5 1.1580.

6 All right. Just give me the
7 Elmo. I'll just use the Elmo.

8 QUESTIONS BY MR. RAFFERTY:

9 Q. You see there it says,
10 "Regulatory affairs update, RNA leadership
11 team, Nate Hartle, senior director,
12 regulatory affairs."

13 Do you see that?

14 A. Yes.

15 Q. November 20, 2015.

16 You see that?

17 A. I do.

18 Q. Okay. Do you recall giving
19 this presentation?

20 A. I'm going to scan through it
21 real quick just so I can refresh --

22 Q. Well, let me -- and feel free
23 to, but I'm just going to -- I'm going to
24 start with the second page, so...

25 A. I -- I believe it was a

1 conference call, maybe. I don't remember
2 exactly all the details from back then, but
3 this is my work, yeah.

4 Q. It doesn't matter. This is
5 your work.

6 A. Yeah.

7 Q. That's all I wanted to get.

8 Okay. So if you look here it
9 says, "Addressing prescription drug abuse and
10 heroin use." And you see it's got a little
11 flow chart, you see?

12 And it goes from the 259
13 million prescriptions of opioids and then --
14 which goes into prescription drug misuse
15 resulting in 1.4 million emergency room
16 visits in 2011.

17 And then that follows with
18 "four out of five users started by
19 misusing" -- in terms of heroin use, "four
20 out of five users started by misusing
21 prescription opioids."

22 You see that?

23 A. I see that.

24 Q. And then overdose, "16,000
25 prescription opioid deaths; heroin overdoses